Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior
- 1 February 1996
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 34 (3), 549-553
- https://doi.org/10.1016/0360-3016(95)02154-x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam RadiationJournal of Urology, 1995
- Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancerUrology, 1994
- Proliferative cell nuclear antigen in postradiotherapy prostate biopsiesInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasesUrology, 1994
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993
- Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling timeInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated PatientsJournal of Urology, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958